• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sean Whooley

Tandem Diabetes Care adds two new members to its board

June 16, 2022 By Sean Whooley

Tandem Diabetes Care tslim_X2_Insulin_Pump_Front_View_Control-IQ_RGB

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it appointed two new independent members to its board of directors. Myoung Cha and Joao Malagueira have been named to the San Diego-based automated insulin delivery technology developer’s board, effective yesterday. “We welcome Joao and Myoung to our board of directors at this exciting stage in Tandem’s evolution,” […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Personnel, Technology Tagged With: Personnel, Personnel Moves, Tandem Diabetes Care

Senseonics wins CE mark approval for 180-day Eversense E3 CGM

June 16, 2022 By Sean Whooley

Marketing image Senseonics Eversense E3 Ascensia Diabetes Care

Senseonics (NYSE:SENS) announced today that it received CE mark for the next-generation Eversense E3 CGM system. Germantown, Maryland-based Senseonics offered a previous-generation continuous glucose monitor (CGM) with a 90-day wear time. Its next-generation Eversense E3 can be used for up to six months (180 days). Europe already had a 180-day Senseonics CGM system available (Eversense […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Regulatory/Compliance, Technology Tagged With: Ascensia Diabetes Care, Senseonics

GI Dynamics EndoBarrier meets endpoints in diabetes, obesity study

June 15, 2022 By Sean Whooley

GI Dynamics Logo

GI Dynamics today announced the results of a study of its EndoBarrier system that met efficacy and safety endpoints. Boston-based GI Dynamics designed its EndoBarrier endoscopically delivered device therapy as a non-surgical, alternative treatment for type 2 diabetes and obesity for patients who do not have adequate control of their conditions through their current medication and […]

Filed Under: Clinical Trials, Diabetes Tagged With: GI Dynamics

Owen Mumford appoints new director of R&D

June 15, 2022 By Sean Whooley

Owen Mumford

Owen Mumford announced today that it appointed Bal Johal as its director of research and development, effective next month. Johal will become the director of R&D for the Woodstock, United Kingdom-based developer of medical devices, including the Aidaptus auto-injector, on July 4, 2022. She has most recently served as VP of product development, quality, regulatory […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Personnel Tagged With: Owen Mumford, Personnel, Personnel Moves

Fresenius Kabi expands compatibility of radio frequency tagged medication

June 14, 2022 By Sean Whooley

Fresenius Kabi logo updated

Fresenius Kabi announced today that its portfolio of radio frequency tagged medications is now compatible with an AmerisourceBergen offering. Lake Zurich, Illinois-based Fresenius Kabi’s growing +RFID portfolio now has compatibility with AmerisourceBergen’s medication tray solution for helping hospitals improve medication inventory visibility and tracking using advanced radiofrequency identification (RFID) technology. Get the full story at […]

Filed Under: Auto-injectors, Business/Financial News, Hospital Care, Radiosurgery Tagged With: AmerisourceBergen, freseniuskabi

InfuSystem, Ventis Pharma enter pain management marketing deal

June 14, 2022 By Sean Whooley

InfuSystem - updated logo

InfuSystem (NSYE:INFU) announced today that it entered into a national sales and marketing agreement with Ventis Pharma. Rochester Hills, Michigan-based InfuSystem’s partnership with Ventis will focus on sales and marketing for the latter’s patented Endura-Kit brand of Enduracaine, a local anesthetic compound. The kit consists of three non-opioid drugs: tetracaine, lidocaine and epinephrine. Ventis Pharma […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals Tagged With: infusystem, Ventis Pharma

Data shows cost benefits with Pear Therapeutics digital therapeutic for opioid use disorder

June 14, 2022 By Sean Whooley

Pear Therapeutics

Pear Therapeutics (Nasdaq:PEAR) today shared real-world data highlighting low costs with its reSET-O prescription digital therapeutic (PDT). Boston-based Pear Therapeutics’ reSET-O represents the only FDA-authorized PDT for the treatment of opioid use disorder (OUD). According to a news release, results from a 12-month, real-world data study of reSET-O demonstrated reduced healthcare resource utilization and associated […]

Filed Under: Big Data, Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Neurological, Patient Monitoring Tagged With: Pear Therapeutics

Early study supports experimental hydrogel injection for chronic low back pain

June 13, 2022 By Sean Whooley

ReGelTec Hydrafil System Hydrogel

A study demonstrated that an experimental hydrogel formulation was safe and effective in substantially relieving chronic low back pain. Research presented at the Society of Interventional Radiology Annual Scientific Meeting in Boston supported the hydrogel, which was injected into spinal discs in an effort to relieve chronic low back pain caused by degenerative disc disease […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Hydrogels, Orthopedics, Pain Management Tagged With: hydrogels, ReGelTec

Dexcom quadruples number of shares

June 13, 2022 By Sean Whooley

Dexcom updated logo

Dexcom (Nasdaq:DXCM) recently filed a restated certificate of incorporation to effect a four-for-one forward stock split. Shares of DXCM were down 0.9% at $293.85 per share at market close on Friday, June 10. Following the stock split, shares moved down 75.33% to $72.50 before the market opened this morning. At market open, shares were down […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Wall Street Beat Tagged With: Dexcom

Data supports Beta Bionics’ iLet bionic pancreas

June 9, 2022 By Sean Whooley

Beta Bionics - updated logo

Beta Bionics announced today that a trial of its iLet bionic pancreas met key endpoints, including reduced HbA1c. Dr. Roy W. Beck and clinical investigators presented the results of the multi-center, randomized Insulin-Only Bionic Pancreas Pivotal Trial (IO BPPT) at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. Read: The biggest stories […]

Filed Under: Auto-injectors, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Beta Bionics

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 99
  • Page 100
  • Page 101
  • Page 102
  • Page 103
  • Interim pages omitted …
  • Page 175
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS